Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure
Journal of Cardiac Failure · 2024-02 · 30 (2) · 340-346
DOI: 10.1016/j.cardfail.2023.05.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2024-02. Verfasst von Veena S Rao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, AstraZeneca.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes. METHODS: We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type III procollagen (PIIINP) in TOPCAT. RESULTS: In the YTCC cohort, there was significant effect modification between higher urine galectin-3 and lower estimated glomerular filtration rates (eGFRs) (Pinteraction = 0.046), such that low eGFR levels had minimal prognostic importance if urine galectin-3 levels were low, but they were important and indicated high risk if urine galectin-3 levels were high. Similar observations were noted in the TOPCAT study (Pinteraction = 0.002). In TOPCAT, urine galectin-3 also positively correlated with urine PIIINP at both baseline (r = 0.43; P < 0.001) and at 12 months (r = 0.42; P < 0.001). CONCLUSIONS: Urine galectin-3 levels correlated with an established biomarker of renal fibrosis in 2 cohorts and was able to differentiate high- vs low-risk phenotypes of chronic kidney disease in HF. These proof-of-concept results indicate that additional biomarker research to differentiate cardiorenal phenotypes is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
- Division of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA; Heart Failure and Heart Transplant Clinic, Hospital de Cardiologia, Instituto Mexicano del Segur…
- Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, TN, USA; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.
- Division of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA. Electronic address: jeffrey.testani@yale.edu.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- AstraZeneca
Zitieren
APA
Rao, V. S., Ivey-Miranda, J. B., Cox, Z. L., Moreno-Villagomez, J., & Testani, J. M. (2024). Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure. Journal of Cardiac Failure, 30(2), 340-346. https://doi.org/10.1016/j.cardfail.2023.05.018
Vancouver
Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Testani JM. Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure. Journal of Cardiac Failure. 2024;30(2):340-346. doi:10.1016/j.cardfail.2023.05.018
BibTeX
@article{Rao2024,
author = {Rao, Veena S and Ivey-Miranda, Juan B and Cox, Zachary L and Moreno-Villagomez, Julieta and Testani, Jeffrey M},
title = {Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure},
journal = {Journal of Cardiac Failure},
year = {2024},
volume = {30},
number = {2},
pages = {340--346},
doi = {10.1016/j.cardfail.2023.05.018}
}
EUVIMED